Novavax Global Commercial Operations and COVID-19 Vaccine Update

Key commercial activities for 2023 fall vaccination season Work to enable reliable access to Nuvaxovid¹ Leverage commercial footprint in priority markets in the Americas and Europe to drive demand Utilize global manufacturing and supply network Deliver differentiated product profile novavax: 1. The trade name Nuvaxovid has not yet been approved by the FDA. © 2023 NOVAVAX. All rights reserved. Priority #1 14

View entire presentation